Affordable Access

deepdyve-link
Publisher Website

Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.

Authors
  • Coppenrath, Valerie Azzopardi1
  • Hydery, Tasmina2
  • 1 1 MCPHS University, Worcester, MA, USA.
  • 2 2 UMass Medical School-Clinical Pharmacy Services (CPS), Shrewsbury, MA, USA.
Type
Published Article
Journal
Annals of Pharmacotherapy
Publisher
SAGE Publications
Publication Date
Jan 01, 2018
Volume
52
Issue
1
Pages
78–85
Identifiers
DOI: 10.1177/1060028017731111
PMID: 28884600
Source
Medline
Keywords
License
Unknown

Abstract

QTERN (dapagliflozin/saxagliptin) tablets are a reasonable option for patients with T2DM not controlled on metformin, but cost, insurance coverage, and a lackluster reduction in A1C will likely limit its use until more data regarding its effects on complications of diabetes and cardiovascular outcomes become available.

Report this publication

Statistics

Seen <100 times